Skip to main content

Vasculitis

      An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.
      There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
      RCT of #upadacitinib in #GCA
      It works to steroid spare
      15 mg > 7.5 mg in outcomes
      Both >>placebo
      Ethically PB

      Dr. John Cush RheumNow

      1 year ago
      RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i? IL17i? JAKi? @eular_org # LBA0001 @Janetbirdope https://t.co/DGOltriVYF
      The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.
      There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.
      Summary of #EULAR2024 #ClinicalPearls

      JAKi have expanding disease data
      ✅ #GCA w #UPA
      ✅ Awaiting data in #SLE w #UPA

      Janet Pope Janetbirdope

      1 year ago
      Summary of #EULAR2024 #ClinicalPearls JAKi have expanding disease data ✅ #GCA w #UPA ✅ Awaiting data in #SLE w #UPA & #Deucravacitinib ✅Use in #JIA ✅No new safety signals @rheumnow @eular_org
      Once in remission with
      #rituximab in #GPA
      How long to resize
      500 mg q6 mo for
      4 years?
      ?longer
      ?less
      #EULAR2024 @eular

      Janet Pope Janetbirdope

      1 year ago
      Once in remission with #rituximab in #GPA How long to resize 500 mg q6 mo for 4 years? ?longer ?less #EULAR2024 @eular_org @RheumNow https://t.co/G4kU3v81je
      #EULARBEST
      RCT of #upadacitinib in #GCA

      It works to steroid spare
      15 mg > 7.5 mg in outcomes
      Both >>placebo

      Janet Pope Janetbirdope

      1 year ago
      #EULARBEST RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i IL17i JAKi @eular_org @RheumNow LBA0001 https://t.co/gy0TEiHxjo
      PMR patients get too much steroid.

      Data across 27 million people in England, n=39,438 with PMR.
      The blue are getting mo

      David Liew drdavidliew

      1 year ago
      PMR patients get too much steroid. Data across 27 million people in England, n=39,438 with PMR. The blue are getting more pred than guidelines. Like everything in rheum: we need to be giving less pred, not more. Lumping PMR in with GCA won’t help. #EULAR2024 POS0411 @RheumNow https://t.co/bsi3lrAafm
      #EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characte

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year ago
      #EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the first 3mths only @RheumNow https://t.co/dCzD21589S
      EULAR Abstract Archive

      OP0283 (2024)
      LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP O

      Peter Nash drpnash

      1 year ago
      EULAR Abstract Archive OP0283 (2024) LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL 3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
      #EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sus

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year ago
      #EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2
      LBA0001 UPA in GCA- Phase 2 RCT

      15mg UPA with 26w steroid taper showed
      ⬆️ efficacy
      ⬇️ steroid use
      vs placebo wi

      Mrinalini Dey DrMiniDey

      1 year ago
      LBA0001 UPA in GCA- Phase 2 RCT 15mg UPA with 26w steroid taper showed ⬆️ efficacy ⬇️ steroid use vs placebo with 52w steroid taper Potential new target on the horizon for #GCA?? @RheumNow #EULAR2024
      Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @

      Rheumatology & Rheumatology Advances in Practice RheumJnl

      1 year ago
      Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀 ➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx
      ×